NO20076086L - Formuleringer for endring av de biofysiske egenskapene til slimhinnene - Google Patents
Formuleringer for endring av de biofysiske egenskapene til slimhinneneInfo
- Publication number
- NO20076086L NO20076086L NO20076086A NO20076086A NO20076086L NO 20076086 L NO20076086 L NO 20076086L NO 20076086 A NO20076086 A NO 20076086A NO 20076086 A NO20076086 A NO 20076086A NO 20076086 L NO20076086 L NO 20076086L
- Authority
- NO
- Norway
- Prior art keywords
- administered
- formulation
- agents
- formulations
- conductive
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 8
- 239000000203 mixture Substances 0.000 title abstract 8
- 210000004877 mucosa Anatomy 0.000 title abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 239000003443 antiviral agent Substances 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000006258 conductive agent Substances 0.000 abstract 1
- 238000011109 contamination Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 230000007613 environmental effect Effects 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 210000000003 hoof Anatomy 0.000 abstract 1
- 206010022000 influenza Diseases 0.000 abstract 1
- 239000002563 ionic surfactant Substances 0.000 abstract 1
- 208000002551 irritable bowel syndrome Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000030194 mouth disease Diseases 0.000 abstract 1
- 210000004400 mucous membrane Anatomy 0.000 abstract 1
- 208000001797 obstructive sleep apnea Diseases 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000000704 physical effect Effects 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000029058 respiratory gaseous exchange Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 206010041232 sneezing Diseases 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 201000008827 tuberculosis Diseases 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Virology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68235605P | 2005-05-18 | 2005-05-18 | |
| PCT/US2006/019443 WO2006125153A2 (en) | 2005-05-18 | 2006-05-18 | Formulations for alteration of biophysical properties of mucosal lining |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20076086L true NO20076086L (no) | 2008-02-14 |
Family
ID=37401509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20076086A NO20076086L (no) | 2005-05-18 | 2007-11-27 | Formuleringer for endring av de biofysiske egenskapene til slimhinnene |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20070053844A1 (enExample) |
| EP (3) | EP1906922A2 (enExample) |
| JP (2) | JP2008540680A (enExample) |
| KR (1) | KR20080018872A (enExample) |
| CN (2) | CN102327285A (enExample) |
| AU (1) | AU2006247077A1 (enExample) |
| BR (1) | BRPI0609924A2 (enExample) |
| CA (1) | CA2608752A1 (enExample) |
| EA (1) | EA016072B1 (enExample) |
| IL (1) | IL187427A0 (enExample) |
| NO (1) | NO20076086L (enExample) |
| NZ (2) | NZ564110A (enExample) |
| WO (1) | WO2006125153A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050207983A1 (en) | 2004-03-05 | 2005-09-22 | Pulmatrix, Inc. | Formulations decreasing particle exhalation |
| JP2012522009A (ja) * | 2009-03-26 | 2012-09-20 | パルマトリックス，インコーポレイテッド | 肺炎および人工呼吸器関連気管気管支炎を治療および予防するための方法 |
| US20120064126A1 (en) * | 2009-03-26 | 2012-03-15 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
| WO2010111640A2 (en) * | 2009-03-26 | 2010-09-30 | Pulmatrix, Inc. | Anti-influenza formulations and methods |
| KR20120015295A (ko) * | 2009-03-26 | 2012-02-21 | 풀매트릭스 인코퍼레이티드 | 점막 내층의 생물물리학적 성질의 변경을 위한 구연산 칼슘 및 젖산 칼슘 제형 |
| RU2011137961A (ru) * | 2009-03-26 | 2013-05-10 | Пулмэтрикс, Инк. | Фармацевтические составы и способы лечения инфекций дыхательных путей |
| EP2448571B1 (en) | 2010-08-30 | 2013-06-12 | Pulmatrix, Inc. | Respirably dry powder comprising calcium lactate, sodium chloride and leucine |
| JP5877201B2 (ja) | 2010-08-30 | 2016-03-02 | パルマトリックス，インコーポレイテッド | 肺疾患を治療するための乾燥粉末製剤および方法 |
| MX354828B (es) | 2010-09-29 | 2018-03-22 | Pulmatrix Operating Co Inc | Polvos secos de cationes metálicos monovalentes para inhalación. |
| ES2710537T3 (es) | 2010-09-29 | 2019-04-25 | Pulmatrix Operating Co Inc | Polvos secos catiónicos |
| US20140336159A1 (en) | 2011-10-07 | 2014-11-13 | Pulmatrix, Inc. | Methods for treating and diagnosing respiratory tract infections |
| CN109999013A (zh) | 2012-02-29 | 2019-07-12 | 普马特里克斯营业公司 | 可吸入干粉剂 |
| JP6473738B2 (ja) | 2013-04-01 | 2019-02-20 | パルマトリックス，インコーポレイテッド | チオトロピウム乾燥粉末 |
| US9987235B2 (en) * | 2013-08-01 | 2018-06-05 | Nicholas L. Abbott | Methods and compositions for modifying mucous membranes |
| CA2965759C (en) | 2014-10-31 | 2023-12-12 | Glaxosmithkline Intellectual Property Development Limited | Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials |
| CA3004908A1 (en) * | 2015-11-18 | 2017-05-26 | The Board Of Trustees Of The Leland Stanford Junior University | B-1a lymphocyte and/or macrophage targeting and activation to treat medical conditions with inflammatory or autoimmune components |
| KR20200108862A (ko) * | 2018-01-11 | 2020-09-21 | 엠피세마 솔루션스 비브이 | 폐기종과 다른 형태의 ｃｏｐｄ의 치료를 위한 조성물과 방법 |
| EP3846825A4 (en) | 2018-09-05 | 2022-11-02 | Sensory Cloud, LLC | FORMULATIONS AND COMPOSITIONS FOR ORTHO- AND/OR RETRO-NASAL DELIVERY AND RELATED SYSTEMS, METHODS AND ARTICLES |
| US12128067B2 (en) | 2018-11-29 | 2024-10-29 | Yildiz Teknik Universitesi | Nasal solution with closed basin natural spring water characteristic and method for obtaining said nasal solution |
| US20230218661A1 (en) * | 2022-01-10 | 2023-07-13 | Sensory Cloud, Inc. | Isotonic or hypertonic salt-based compositions, treatments, devices, and articles for delivery of same to larynx |
| US20220000767A1 (en) * | 2020-07-06 | 2022-01-06 | Sensory Cloud, Inc. | Nasal hygiene compositions, antimicrobial treatments, devices, and articles for delivery of same to the nose, trachea and main bronchi |
| US20220051592A1 (en) * | 2020-08-17 | 2022-02-17 | Massachusetts Institute Of Technology | Respiratory system simulator systems and methods |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3229179C2 (de) * | 1982-08-05 | 1986-04-17 | A. Nattermann & Cie GmbH, 5000 Köln | Lungensurfactant |
| US4637815A (en) * | 1985-08-06 | 1987-01-20 | Lemole Gerald M | Irrigational hemostatic solution |
| US5230884A (en) * | 1990-09-11 | 1993-07-27 | University Of Wales College Of Cardiff | Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol formulations |
| US5175152A (en) * | 1990-09-28 | 1992-12-29 | Singh Nikhilesh N | Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form |
| US5571535A (en) * | 1990-11-30 | 1996-11-05 | Flowers; Marianne | Treatment of topical infections |
| US5466680A (en) * | 1992-03-26 | 1995-11-14 | Cytologics, Inc. | Method and compositions for enhancing white blood cell functioning on a mucosal or cutaneous surface |
| US5898037A (en) * | 1992-11-13 | 1999-04-27 | Marx; Alvin J. | Formulations of magnesium compounds for local application and methods of treatment using the same |
| US5709202A (en) | 1993-05-21 | 1998-01-20 | Aradigm Corporation | Intrapulmonary delivery of aerosolized formulations |
| AUPM411494A0 (en) * | 1994-02-25 | 1994-03-24 | Central Sydney Area Health Service | Method and device for the provocation of upper or lower airway narrowing and/or the induction of sputum |
| US5633003A (en) * | 1994-03-31 | 1997-05-27 | Cantor; Jerome O. | Use of intratracheally administered hyaluronic acid to ameliorate emphysema |
| US6290991B1 (en) * | 1994-12-02 | 2001-09-18 | Quandrant Holdings Cambridge Limited | Solid dose delivery vehicle and methods of making same |
| KR100386392B1 (ko) * | 1994-10-14 | 2003-10-11 | 야마노우치세이야쿠 가부시키가이샤 | 아졸유도체및이를포함하는약제학적조성물 |
| AU3705695A (en) * | 1994-10-26 | 1996-05-23 | Wellcome Foundation Limited, The | Pharmaceutical composition comprising atovaquone |
| US5654007A (en) * | 1995-06-07 | 1997-08-05 | Inhale Therapeutic Systems | Methods and system for processing dispersible fine powders |
| US5628984A (en) * | 1995-07-31 | 1997-05-13 | University Of North Carolina At Chapel Hill | Method of detecting lung disease |
| US6083922A (en) * | 1996-04-02 | 2000-07-04 | Pathogenesis, Corp. | Method and a tobramycin aerosol formulation for treatment prevention and containment of tuberculosis |
| USRE37053E1 (en) * | 1996-05-24 | 2001-02-13 | Massachusetts Institute Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| US5874064A (en) * | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
| US6254854B1 (en) * | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
| US5985309A (en) * | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
| US5855913A (en) * | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
| DE19653969A1 (de) * | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Kg | Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole |
| HRP20000666A2 (en) * | 1998-04-08 | 2001-08-31 | Lilly Co Eli | Pulmonary and nasal delivery of raloxifene |
| US5883084A (en) * | 1998-06-08 | 1999-03-16 | Clarion Pharmaceuticals Inc. | Treatment of respiratory diseases utilizing α-tocopheryl-phosphocholine |
| FR2780285B1 (fr) * | 1998-06-29 | 2001-10-05 | Goemar Lab Sa | Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments anti-inflammatoires a base de ces solutions |
| US6333051B1 (en) * | 1998-09-03 | 2001-12-25 | Supratek Pharma, Inc. | Nanogel networks and biological agent compositions thereof |
| EP1173245B1 (en) * | 1999-05-03 | 2004-09-01 | Battelle Memorial Institute | Compositions for aerosolization and inhalation |
| US6858199B1 (en) * | 2000-06-09 | 2005-02-22 | Advanced Inhalation Research, Inc. | High efficient delivery of a large therapeutic mass aerosol |
| AU772096B2 (en) * | 2000-03-14 | 2004-04-08 | Sumika Enviro-Science Co., Ltd. | Method for denaturing allergens |
| JP3481205B2 (ja) * | 2000-11-24 | 2003-12-22 | 松下電器産業株式会社 | インバータ制御用半導体装置および制御方法 |
| AU2002245181B2 (en) * | 2000-12-21 | 2006-06-29 | Nektar Therapeutics | Pulmonary delivery of polyene antifungal agents |
| US6667344B2 (en) * | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| US20030232019A1 (en) * | 2002-02-22 | 2003-12-18 | Advanced Inhalation Research, Inc. | Inhalable formulations for sustained release |
| EP1531795A4 (en) * | 2002-05-02 | 2011-02-23 | Harvard College | FORMULATIONS FOR LIMITING THE RETENTION OF LUNG INFECTIONS |
| WO2003094900A1 (en) * | 2002-05-13 | 2003-11-20 | Alexza Molecular Delivery Corporation | Delivery of drug amines through an inhalation route |
| EP1511467A1 (en) * | 2002-06-10 | 2005-03-09 | Elan Pharma International Limited | Nanoparticulate polycosanol formulations and novel polycosanol combinations |
| US7534781B2 (en) * | 2003-03-21 | 2009-05-19 | Dsm Ip Assets B.V. | Crystalline amoxicillin trihydrate powder |
| JP2009514779A (ja) * | 2003-07-11 | 2009-04-09 | グラクソ グループ リミテッド | 医薬製剤 |
| GB0324897D0 (en) * | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Composition |
| US20050207983A1 (en) | 2004-03-05 | 2005-09-22 | Pulmatrix, Inc. | Formulations decreasing particle exhalation |
| SE528121C2 (sv) * | 2004-03-29 | 2006-09-05 | Mederio Ag | Preparering av torrpulver för på förhand uppmätt DPI |
| US20070275091A1 (en) * | 2004-03-30 | 2007-11-29 | Malcolm King | Compositions And Methods For Improved Mucus Function |
| WO2006014930A2 (en) * | 2004-07-26 | 2006-02-09 | Cotherix, Inc. | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation |
| US20070202051A1 (en) * | 2006-02-10 | 2007-08-30 | Pari Gmbh | Aerosols for sinunasal drug delivery |
| GB0818476D0 (en) * | 2008-10-09 | 2008-11-12 | Vectura Delivery Device Ltd | Inhaler |
| WO2010111640A2 (en) * | 2009-03-26 | 2010-09-30 | Pulmatrix, Inc. | Anti-influenza formulations and methods |
-
2006
- 2006-05-18 WO PCT/US2006/019443 patent/WO2006125153A2/en not_active Ceased
- 2006-05-18 EP EP06770654A patent/EP1906922A2/en not_active Withdrawn
- 2006-05-18 CN CN2011102255478A patent/CN102327285A/zh active Pending
- 2006-05-18 NZ NZ564110A patent/NZ564110A/en unknown
- 2006-05-18 US US11/419,165 patent/US20070053844A1/en not_active Abandoned
- 2006-05-18 AU AU2006247077A patent/AU2006247077A1/en not_active Abandoned
- 2006-05-18 BR BRPI0609924-6A patent/BRPI0609924A2/pt not_active IP Right Cessation
- 2006-05-18 JP JP2008512543A patent/JP2008540680A/ja active Pending
- 2006-05-18 KR KR1020077027567A patent/KR20080018872A/ko not_active Ceased
- 2006-05-18 EP EP10014830A patent/EP2308469A1/en not_active Withdrawn
- 2006-05-18 CA CA002608752A patent/CA2608752A1/en not_active Abandoned
- 2006-05-18 NZ NZ593475A patent/NZ593475A/xx unknown
- 2006-05-18 CN CNA2006800261749A patent/CN101237853A/zh active Pending
- 2006-05-18 EA EA200702520A patent/EA016072B1/ru not_active IP Right Cessation
- 2006-05-18 EP EP11177874A patent/EP2402001A1/en not_active Withdrawn
-
2007
- 2007-11-15 IL IL187427A patent/IL187427A0/en unknown
- 2007-11-27 NO NO20076086A patent/NO20076086L/no not_active Application Discontinuation
-
2012
- 2012-06-19 JP JP2012137900A patent/JP2012176990A/ja active Pending
-
2014
- 2014-11-14 US US14/541,648 patent/US20150196589A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2402001A1 (en) | 2012-01-04 |
| KR20080018872A (ko) | 2008-02-28 |
| CN101237853A (zh) | 2008-08-06 |
| IL187427A0 (en) | 2011-08-01 |
| CN102327285A (zh) | 2012-01-25 |
| WO2006125153A2 (en) | 2006-11-23 |
| CA2608752A1 (en) | 2006-11-23 |
| JP2008540680A (ja) | 2008-11-20 |
| EA200702520A1 (ru) | 2008-06-30 |
| EP1906922A2 (en) | 2008-04-09 |
| US20150196589A1 (en) | 2015-07-16 |
| US20070053844A1 (en) | 2007-03-08 |
| NZ593475A (en) | 2012-12-21 |
| NZ564110A (en) | 2010-06-25 |
| WO2006125153A3 (en) | 2008-02-28 |
| BRPI0609924A2 (pt) | 2010-05-11 |
| JP2012176990A (ja) | 2012-09-13 |
| AU2006247077A1 (en) | 2006-11-23 |
| EP2308469A1 (en) | 2011-04-13 |
| EA016072B1 (ru) | 2012-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20076086L (no) | Formuleringer for endring av de biofysiske egenskapene til slimhinnene | |
| NO20076083L (no) | Mukoadhesive xyloglukaninneholdende formuleringer som er anvendelige i medisinske anordninger og i farmasoytiske formuleringer | |
| CN1352550A (zh) | 酸性缓冲的鼻用喷雾剂 | |
| JP2005537234A5 (enExample) | ||
| EP1797881A4 (en) | MEDICAL COMPOSITION | |
| NO20056223L (no) | Preparat til behandling av infeksjon hos kveg og svin | |
| ATE471144T1 (de) | Intranasale verabreichung von schnell wirkendem insulin | |
| CY1115940T1 (el) | Παραγωγα υποκατεστημενου φαινυλαλκανοϊκου οξεος και η χρηση τους για τη θεραπευτικη αντιμετωπιση αναπνευστικων ασθενειων | |
| EA200800798A1 (ru) | Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха | |
| WO2007070677A3 (en) | Pharmaceutical compositions and methods for treating or preventing oxalate-related disease | |
| WO2017212422A1 (en) | Topical compositions comprising carbomer for the treatment and prevention of viral infections and allergic conditions | |
| NO20055144L (no) | Preparat for behandling av mikrobielle og parasittiske infeksjoner hos storfe og andre dyr. | |
| ATE366107T1 (de) | Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen | |
| NO20071636L (no) | Flytende allergivaksineformulering for oromukosal administrering | |
| JP2006507295A5 (enExample) | ||
| CN109152754A (zh) | 用于治疗/预防鼻充血的羧酸 | |
| TW202227104A (zh) | 預防感染之組合物 | |
| GB2605247A (en) | Method of prophylaxis of coronavirus and/or respiratory syncytial virus | |
| NZ597657A (en) | Use sulphur particles less than 300 microns and sodium lignin sulfonate for treating diseases casused by microbial pathogenic infections | |
| KR101602516B1 (ko) | 정전기를 띤 다중 작용 비강 적용물, 제품 및 방법 | |
| CN116568138A (zh) | 用于消毒、治疗和预防微生物感染的组合物和方法 | |
| WO2025087269A1 (en) | New short-chain peptides and derivatives thereof | |
| SE0203349D0 (sv) | New use | |
| BRPI0414223A (pt) | uso de extratos de gentiana lutea como um agente antimicrobiano | |
| TWI836258B (zh) | 預防冠狀病毒及/或呼吸道融合病毒感染的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |